Pure Global AI
Applicant profile

Terumo Europe N.V.

Terumo
Hong Kong MDACSBelgium7 registered devicesMay 06, 2011 – Oct 25, 2023
VerifiedMDD (Medical Device Division) · MDACS registry
7
Total devices
2
Risk classes
2011
First registration
2023
Most recent
Applicant overview
Applicant (EN)
Terumo Europe N.V.
Applicant (ZH)
Terumo
Country
Belgium
比利时
Address
Interleuvenlaan 40, 3001 Leuven, Belgium
Interleuvenlaan 40, 3001 鲁汶, 比利时
Timeline
First registration
May 06, 2011
Most recent
Oct 25, 2023
Regulatory footprint
Search Terumo Europe N.V. across other regulatory registries
ThailandEuropean UnionColombiaSouth KoreaCanadaEcuador
Risk class breakdown
II2
IV5
Recent MDACS registrations
Latest 15 devices linked to this applicant
Stents, Vascular, Coronary, Balloon-Expandable, Drug-Eluting
血管支架、冠状动脉支架、球囊扩张支架、药物洗脱支架
Oct 25, 2023
Risk class
IV
Authorised rep
Terumo China (Hong Kong) Limited泰尔茂中国(香港)有限公司
Stents, Vascular, Coronary, Balloon-Expandable, Drug-Eluting
血管支架、冠状动脉支架、球囊扩张支架、药物洗脱支架
Jul 26, 2023
Risk class
IV
Authorised rep
Terumo China (Hong Kong) Limited泰尔茂中国(香港)有限公司
Stents, Vascular, Coronary, Balloon-Expandable, Drug-Eluting
血管支架、冠状动脉支架、球囊扩张支架、药物洗脱支架
May 27, 2020
Risk class
IV
Authorised rep
Terumo China (Hong Kong) Limited泰尔茂中国(香港)有限公司
Catheters, Vascular, Infusion, Peripheral
导管,血管,输液,外周
Feb 25, 2019
Risk class
II
Authorised rep
Terumo China (Hong Kong) Limited泰尔茂中国(香港)有限公司
Intravenous Administration Sets, Scalp-Vein
静脉给药套装,头皮静脉
Feb 04, 2014
Risk class
II
Authorised rep
Terumo China (Hong Kong) Limited泰尔茂中国(香港)有限公司
Stents, Vascular, Coronary, Balloon-Expandable, Drug-Eluting
血管支架、冠状动脉支架、球囊扩张支架、药物洗脱支架
Feb 04, 2014
Risk class
IV
Authorised rep
Terumo China (Hong Kong) Limited泰尔茂中国(香港)有限公司
Stents, Vascular, Coronary
支架,血管,冠状动脉
May 06, 2011
Risk class
IV
Authorised rep
Terumo China (Hong Kong) Limited泰尔茂中国(香港)有限公司
About this profile

Terumo Europe N.V. is associated with 7 medical devices registered under the Hong Kong Medical Device Administrative Control System (MDACS). Explore bilingual product names, risk classes, authorised representatives, and life-cycle milestones.